03:20 , Aug 17, 2018 |  BC Week In Review  |  Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
14:02 , Aug 14, 2018 |  BC Extra  |  Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
21:09 , Apr 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Cell culture and mouse studies suggest promoting the expression of SIRT1 could help treat Alzheimer’s disease and other neurodegenerative tauopathies. In HEK cells expressing mutant human tau, plasma vector-encoded SIRT1 decreased levels of...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:18 , Nov 14, 2017 |  BC Extra  |  Preclinical News

Hybrid T cells show anticancer effects

A study published in...
16:06 , Jun 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting SIRT1 could help treat osteoarthritis. In cartilage samples from patients, levels of activated DOT1L , a negative regulator of SIRT1, were lower than in samples from...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α , to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While...
07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Sirtuins forge ahead

Since sirtuins hit the scene as modulators of numerous cellular pathways over 20 years ago, the enzymes have been implicated in metabolic diseases, aging and cancer. Now Forge Life Science LLC has licensed findings from...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sirtuin 1 (SIRT1); ataxin 3 (ATXN3)

Neurology INDICATION: Ataxia Patient sample and mouse studies suggest promoting SIRT1 activity could help treat spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease caused by mutant ATXN3 encoding polyglutamine repeats. Levels of SIRT1 were lower...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: SNPs on chromosome 10 as susceptibility loci for major depressive disorder (MDD)

Biomarkers TECHNOLOGY: SNPs Genetic sequencing studies identified two new susceptibility loci on chromosome 10 that could help predict risk of MDD. In 5,303 Han Chinese women with recurrent MDD and 5,337 non-depressed controls and validation...